Bearsden, United Kingdom

Eric O Aboagye

This inventor holds 1 USPTO granted patent, plus 1 CIPO patent. Top assignee: Sri International. Active years: 1998.


% Patents Active = 100.0


Average Co-Inventor Count = 5.0

ph-index = 1

Forward Citations = 5(Granted Patents)


Company Filing History:


Years Active: 1998

Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: Innovations of Eric O Aboagye in Tumor Detection

Introduction

Eric O Aboagye is a notable inventor based in Bearsden, GB. He has made significant contributions to the field of medical diagnostics, particularly in the detection of hypoxic tumor cells. His innovative work has led to the development of novel compounds that can aid in cancer detection.

Latest Patents

Eric O Aboagye holds 1 patent for his invention titled "Fluorinated 2-nitroimidazole analogs for detecting hypoxic tumor cells." This patent provides agents that are useful for detecting hypoxic tumor cells. The compounds he developed have a specific structural formula and include methods for using these compounds in clinical settings. Additionally, pharmaceutical compositions formulated with these novel compounds are also part of his patent.

Career Highlights

Eric is currently associated with SRI International, where he continues to work on innovative solutions in the medical field. His research focuses on improving cancer detection methods, which can significantly impact patient outcomes.

Collaborations

Throughout his career, Eric has collaborated with notable colleagues, including Michael Tracy and Andrew B Kelson. These collaborations have further enhanced the research and development of his innovative compounds.

Conclusion

Eric O Aboagye's contributions to the field of tumor detection exemplify the importance of innovation in medical diagnostics. His work not only advances scientific knowledge but also holds the potential to improve cancer detection and treatment strategies.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…